{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:07:28Z","timestamp":1790082448378,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatic arterial infusion (HAI) of floxuridine is an effective adjuvant therapy for colorectal liver metastases (CRLM) following complete resection, but its use is limited by hepatobiliary toxicity. Dosing characteristics, factors associated with dose reductions, and the impact of starting dose on hepatobiliary toxicity and survival in the adjuvant setting are poorly described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From 2015 to 2024, patients who received adjuvant HAI floxuridine after complete CRLM resection at City of Hope were included. Hepatobiliary toxicity and oncologic outcomes of standard (0.12\u00a0mg\/kg\/day) versus reduced (0.08\u00a0mg\/kg\/day) dosing were compared. Extent of hepatobiliary toxicity, factors associated with dose reductions, hepatic recurrence-free survival (H-RFS), and overall survival (OS) were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-one patients were included (median age 52). Dosing information was available for 69 patients with 40 (58%) receiving the standard dose and 29 (42%) receiving the reduced dose. Patients receiving the standard dose had significantly higher rates of hepatobiliary toxicity, including increased transaminases, alkaline phosphatase, and bilirubin levels. Biliary sclerosis requiring endoscopic intervention occurred only in the standard-dose group (\n                      <jats:italic>n<\/jats:italic>\n                      = 4, 10%). Dose reductions were more frequent in the standard-dose group (82% vs. 53%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.04). Despite lower cumulative floxuridine exposure, the reduced dose did not compromise oncologic outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A reduced starting floxuridine dose (0.08\u00a0mg\/kg\/day) is associated with lower hepatobiliary toxicity without compromising survival after complete resection of CRLM. These findings support adopting the reduced dose as a new standard in the adjuvant treatment of resected CRLM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-17783-y","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:04:15Z","timestamp":1753200255000},"page":"9526-9533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reduced Floxuridine Dose Limits Hepatobiliary Toxicity Without Negatively Impacting Survival After Resection of Colorectal Cancer Liver Metastases"],"prefix":"10.1245","volume":"32","author":[{"given":"Kevin P.","family":"Labadie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana A.","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Meshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Cecilia","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence D.","family":"Wagman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuman","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan G.","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6279-7981","authenticated-orcid":false,"given":"Laleh G.","family":"Melstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"1","key":"17783_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin."},{"issue":"7","key":"17783_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669\u201385.","journal-title":"JAMA."},{"issue":"1","key":"17783_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","volume":"18","author":"J Engstrand","year":"2018","unstructured":"Engstrand J, et al. Colorectal cancer liver metastases - a population-based study on incidence, management and survival. BMC Cancer. 2018;18(1):78.","journal-title":"BMC Cancer."},{"issue":"4","key":"17783_CR4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1245\/s10434-010-1409-1","volume":"18","author":"M D'Angelica","year":"2011","unstructured":"D\u2019Angelica M, et al. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol. 2011;18(4):1096\u2013103.","journal-title":"Ann Surg Oncol."},{"issue":"29","key":"17783_CR5","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","volume":"25","author":"JS Tomlinson","year":"2007","unstructured":"Tomlinson JS, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575\u201380.","journal-title":"J Clin Oncol."},{"issue":"3","key":"17783_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/bjs\/znac461","volume":"110","author":"GE Wensink","year":"2023","unstructured":"Wensink GE, et al. Predicting early extrahepatic recurrence after local treatment of colorectal liver metastases. Br J Surg. 2023;110(3):362\u201371.","journal-title":"Br J Surg."},{"issue":"2","key":"17783_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/SLA.0000000000003248","volume":"272","author":"S Gholami","year":"2020","unstructured":"Gholami S, et al. Adjuvant hepatic artery infusion chemotherapy is associated with improved survival regardless of kras mutation status in patients with resected colorectal liver metastases: a retrospective analysis of 674 patients. Ann Surg. 2020;272(2):352\u20136.","journal-title":"Ann Surg."},{"issue":"17","key":"17783_CR8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.2016.71.8346","volume":"35","author":"B Groot Koerkamp","year":"2017","unstructured":"Groot Koerkamp B, et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. J Clin Oncol. 2017;35(17):1938\u201344.","journal-title":"J Clin Oncol."},{"issue":"27","key":"17783_CR9","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","volume":"341","author":"N Kemeny","year":"1999","unstructured":"Kemeny N, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039\u201348.","journal-title":"N Engl J Med."},{"issue":"6","key":"17783_CR10","first-page":"1499","volume":"20","author":"MM Kemeny","year":"2002","unstructured":"Kemeny MM, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy\u2013an intergroup study. J Clin Oncol. 2002;20(6):1499\u2013505.","journal-title":"J Clin Oncol."},{"issue":"2","key":"17783_CR11","first-page":"176","volume":"10","author":"WD Ensminger","year":"1983","unstructured":"Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983;10(2):176\u201382.","journal-title":"Semin Oncol."},{"issue":"5","key":"17783_CR12","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1158\/1535-7163.MCT-08-0709","volume":"8","author":"DG Power","year":"2009","unstructured":"Power DG, Kemeny NE. The role of floxuridine in metastatic liver disease. Mol Cancer Ther. 2009;8(5):1015\u201325.","journal-title":"Mol Cancer Ther."},{"issue":"5","key":"17783_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1245\/s10434-011-2102-8","volume":"19","author":"K Ito","year":"2012","unstructured":"Ito K, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19(5):1609\u201317.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"17783_CR14","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1200\/JCO.1984.2.6.595","volume":"2","author":"N Kemeny","year":"1984","unstructured":"Kemeny N, et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol. 1984;2(6):595\u2013600.","journal-title":"J Clin Oncol."},{"issue":"2","key":"17783_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1245\/s10434-013-3275-0","volume":"21","author":"A Cercek","year":"2014","unstructured":"Cercek A, et al. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. Ann Surg Oncol. 2014;21(2):479\u201386.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"17783_CR16","doi-asserted-by":"publisher","first-page":"7362","DOI":"10.1245\/s10434-023-14207-7","volume":"30","author":"SJ Judge","year":"2023","unstructured":"Judge SJ, et al. Current practices in hepatic artery infusion (HAI) chemotherapy: an international survey of the HAI consortium research network. Ann Surg Oncol. 2023;30(12):7362\u201370.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"17783_CR17","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1245\/s10434-024-15729-4","volume":"31","author":"IR Schwantes","year":"2024","unstructured":"Schwantes IR, et al. A modified floxuridine reduced-dose protocol for patients with unresectable colorectal liver metastases treated with hepatic arterial infusion. Ann Surg Oncol. 2024;31(10):6537\u201345.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"17783_CR18","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139.","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"17783_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309\u201318.","journal-title":"Ann Surg."},{"issue":"1","key":"17783_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/SLA.0000000000002064","volume":"267","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, et al. The tumor burden score: a new, \u201cMetro-ticket\u201d prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. 2018;267(1):132\u201341.","journal-title":"Ann Surg."},{"issue":"3","key":"17783_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1365-182X(17)30755-4","volume":"2","author":"SM Strasberg","year":"2000","unstructured":"Strasberg SM, et al. The brisbane 2000 terminology of liver anatomy and resections. HPB (Oxford). 2000;2(3):333\u20139.","journal-title":"HPB (Oxford)."},{"issue":"2","key":"17783_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg."},{"issue":"7","key":"17783_CR23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/annonc\/mdn769","volume":"20","author":"N Kemeny","year":"2009","unstructured":"Kemeny N, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009;20(7):1236\u201341.","journal-title":"Ann Oncol."},{"issue":"2","key":"17783_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/OP.23.00374","volume":"20","author":"D Rao","year":"2024","unstructured":"Rao D, et al. Case-based clinical guidance on dosing and management of the hepatic artery infusion chemotherapy pump. JCO Oncol Pract. 2024;20(2):187\u201394.","journal-title":"JCO Oncol Pract."},{"issue":"5","key":"17783_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1002\/1097-0142(19820901)50:5<850::AID-CNCR2820500508>3.0.CO;2-2","volume":"50","author":"RM Barone","year":"1982","unstructured":"Barone RM, et al. Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases. Cancer. 1982;50(5):850\u201362.","journal-title":"Cancer."},{"issue":"5","key":"17783_CR26","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/1097-0142(19800301)45:5<866::AID-CNCR2820450507>3.0.CO;2-3","volume":"45","author":"H Buchwald","year":"1980","unstructured":"Buchwald H, et al. Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer. 1980;45(5):866\u20139.","journal-title":"Cancer."},{"issue":"9","key":"17783_CR27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","volume":"24","author":"NE Kemeny","year":"2006","unstructured":"Kemeny NE, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395\u2013403.","journal-title":"J Clin Oncol."},{"issue":"11","key":"17783_CR28","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1200\/JCO.1990.8.11.1885","volume":"8","author":"LD Wagman","year":"1990","unstructured":"Wagman LD, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol. 1990;8(11):1885\u201393.","journal-title":"J Clin Oncol."},{"issue":"1","key":"17783_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek A, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):60\u20137.","journal-title":"JAMA Oncol."},{"issue":"2","key":"17783_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","volume":"261","author":"MI D'Angelica","year":"2015","unstructured":"D\u2019Angelica MI, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261(2):353\u201360.","journal-title":"Ann Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17783-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17783-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17783-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:18:13Z","timestamp":1762352293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17783-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["17783"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17783-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}